Skip to main navigation

FibroGen China
Newsroom
Contact

About Us
Focus Areas
Pipeline
Clinical Trials
Careers
Investors and Media
Investor Relations

MENU MENU

About Us
Focus Areas
Pipeline
Clinical Trials
Careers
Investors and Media
Iphone menu

FibroGen China
Newsroom
Contact

Investors and Media

Press Releases

Keyword Search

Year

December 22, 2020
FibroGen Advances Phase 3 Clinical Development of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis with Initiation of ZEPHYRUS-2
December 18, 2020
FibroGen Provides Regulatory Update on Roxadustat
December 2, 2020
FibroGen to Present Safety and Efficacy Analyses from Roxadustat Global Phase 3 Program at American Society of Hematology Annual Meeting
December 1, 2020
FibroGen Announces Retirement of K. Peony Yu, M.D., and Appointment of Mark Eisner, M.D., M.P.H. as Chief Medical Officer
November 27, 2020
Astellas Receives Approval of EVRENZO® (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis
November 6, 2020
FibroGen to Present at Upcoming Investor Conferences
November 5, 2020
FibroGen Reports Third Quarter 2020 Financial Results
October 29, 2020
FibroGen to Report Third Quarter 2020 Financial Results
October 22, 2020
FibroGen Presents Late-Breaker Abstract Results on Associations between Hemoglobin Levels and Cardiovascular Outcomes in Roxadustat-Treated Patients with Anemia of Chronic Kidney Disease (CKD)
October 14, 2020
FibroGen to Present New Efficacy and Safety Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week 2020 Reimagined
September 8, 2020
FibroGen Appoints Percy Carter, MBA, PhD, as Chief Scientific Officer
September 1, 2020
FibroGen to Present at Upcoming Investor Conferences
August 11, 2020
FibroGen Announces First Patient Enrolled in Pamrevlumab Phase 3 Clinical Trial in Patients with Duchenne Muscular Dystrophy
August 6, 2020
FibroGen Reports Second Quarter 2020 Financial Results
August 6, 2020
FibroGen Announces New Appointments to its Board of Directors
July 23, 2020
FibroGen to Report Second Quarter 2020 Financial Results
June 23, 2020
FibroGen Announces First Patient Enrolled in Pamrevlumab Clinical Trial in Patients Hospitalized in U.S. with Acute COVID-19
June 22, 2020
FibroGen Appoints Thane Wettig as Chief Commercial Officer
June 8, 2020
FibroGen Announces New Roxadustat Data Presented at 2020 ERA-EDTA Virtual Congress
June 8, 2020
FibroGen Announces First Patient Enrolled in Pamrevlumab Clinical Trial in Patients Hospitalized in Italy with Severe COVID-19
May 27, 2020
FibroGen to Present at Upcoming Investor Conferences
May 21, 2020
European Medicines Agency Accepts Astellas’ Marketing Authorization Application for Roxadustat
May 8, 2020
FibroGen to Present at Bank of America Securities 2020 Health Care Conference
May 7, 2020
FibroGen Reports First Quarter 2020 Financial Results
April 24, 2020
FibroGen To Report First Quarter 2020 Financial Results
April 20, 2020
FibroGen Reports UK Court Ruling
March 2, 2020
FibroGen Reports Fourth Quarter and Full Year 2019 Financial Results
February 18, 2020
FibroGen to Report Fourth Quarter and Full Year 2019 Financial Results
February 11, 2020
FibroGen Announces U.S. FDA Acceptance of New Drug Application for Roxadustat for the Treatment of Anemia of Chronic Kidney Disease
February 11, 2020
FibroGen to Present at 9th Annual SVB Leerink Global Healthcare Conference
January 30, 2020
Astellas Submits Supplemental New Drug Application for Approval of Evrenzo® (roxadustat) for the Treatment of Anemia Associated with Chronic Kidney Disease in Non-Dialysis Dependent Patients in Japan
January 6, 2020
FibroGen Names Enrique Conterno as Chief Executive Officer

Investors and Media

Investor Overview
Stock Information
Press Releases
Events & Presentations
Corporate Governance
SEC Filings
Financial Information
Shareholder Services
Investor FAQs

FibroGen Inc.

Volume:

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor and Media Contact

Media Inquiries:
Jennifer Harrington
+1.610.574.9196
jennifer.harrington@gcihealth.com
Investors:
Michael Tung, M.D.
Corporate Strategy / Investor Relations
1.415.978.1434
mtung@fibrogen.com

Shareholder Tools

Print Page
RSS Feeds
E-mail Alerts

About Us

Our Company
Our Strategy
FibroGen China
Executive Team
Board of Directors
Our Partners
Contact Us

Focus Areas

Our Expertise
Anemia
Idiopathic Pulmonary Fibrosis
Pancreatic Cancer
Duchenne Muscular Dystrophy
Corneal Blindness
Publications

Pipeline

R&D Pipeline
Roxadustat
Pamrevlumab
FG-5200

Clinical Trials

Our Priorities
Roxadustat Trials
Pamrevlumab Trials

Careers

Our Culture
Career Opportunities
Notice to Recruiters

Investors & Media

Investor Relations

Investor Overview
Stock Information
News Releases
Events and Presentations
Corporate Governance
SEC Filings
Financial Information
Shareholder Services
Investor FAQs

Terms of Use
Privacy Policy

About Us
Focus Area
Pipeline
Clinical Trials
Investors and Media
Terms of Use
Privacy Notice

© 2021 FibroGen, Inc.
409 Illinois Street, San Francisco, CA 94158